Watts J, Files B
Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA.
Pediatr Hematol Oncol. 2001 Apr-May;18(3):199-204. doi: 10.1080/08880010151114840.
A case of disseminated Langerhans cell histiocytosis with resistant central nervous system (CNS) disease in an adolescent is described. The child presented with visible cranial lesions, emesis, headaches, and short-term memory loss. Diagnostic evaluation revealed multiple osseous lesions in the cranium, ribs, vertebral bodies, and pelvis. The clinical course with complications and response to each therapy are sequentially reviewed. Remission, as evidenced clinically and by magnetic resonance imaging, was ultimately accomplished with 2-chlorodeoxyadenosine (2-CDA). The full course of 2-CDA was not tolerated due to bone marrow suppression. CNS histiocytosis is known to be resistant to therapy. Earlier introduction of 2-CDA for CNS disease might offer more successful treatment with less toxicity than seen in patient.
描述了一例青少年播散性朗格汉斯细胞组织细胞增多症伴耐药性中枢神经系统(CNS)疾病的病例。该患儿出现可见的颅骨病变、呕吐、头痛和短期记忆丧失。诊断评估显示颅骨、肋骨、椎体和骨盆有多处骨病变。依次回顾了并发症的临床病程及对每种治疗的反应。最终通过2-氯脱氧腺苷(2-CDA)实现了临床及磁共振成像证实的缓解。由于骨髓抑制,患者无法耐受2-CDA的全程治疗。已知中枢神经系统组织细胞增多症对治疗耐药。对于中枢神经系统疾病,更早引入2-CDA可能会提供比该患者更成功且毒性更小的治疗。